Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
30 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/kither-biotech-announces-phase-1-clinical-study-of-kit2014-a-novel-inhaled-peptide-therapy-for-cystic-fibrosis-302290900.html
31 Mar 2022
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2022/03/31/2413452/0/en/Kither-Biotech-announces-publication-of-new-data-in-Science-Translational-Medicine.html
Details:
KIT2014 is a peptide-based therapy designed to inhibit PDE3/4, being investigated for the treatment of CF lung disease in adults.
Lead Product(s): KIT2014
Therapeutic Area: Genetic Disease Brand Name: KIT2014
Study Phase: Phase IProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2024
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kither Launches Phase 1 Study of KIT2014 Inhaled Therapy for Cystic Fibrosis
Details : KIT2014 is a peptide-based therapy designed to inhibit PDE3/4, being investigated for the treatment of CF lung disease in adults.
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 30, 2024
Details:
KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflammation.
Lead Product(s): KIT2014
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: KIT2014
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Kither Biotech Announces Publication of New Data in Science Translational Medicine
Details : KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflamma...
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Not Applicable
March 31, 2022
Details:
Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Lead Product(s): KIT2014
Therapeutic Area: Genetic Disease Brand Name: KIT2014
Study Phase: PreclinicalProduct Type: Peptide
Sponsor: Claris Ventures
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing March 16, 2022
Lead Product(s) : KIT2014
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Claris Ventures
Deal Size : $18.5 million
Deal Type : Series B Financing
Kither Biotech Raises €18.5 Million Series B and Appoints Dr. Vincent Metzler as Chief Executive...
Details : Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.
Brand Name : KIT2014
Molecule Type : Peptide
Upfront Cash : Undisclosed
March 16, 2022
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?